Top Biopharmaceutical Companies in Israel

The company is developing innovative oral protein and peptide replacement therapies aimed at enhancing treatment outcomes for patients with chronic diseases, thereby addressing significant unmet clinical needs in the biopharmaceutical sector. Their focus on first-in-class, daily tablet formulations allows for a healthier, injection-free management of conditions, positioning them as a global leader in oral delivery of therapeutic proteins.

BTG is a pioneer in the development and manufacture of biopharmaceuticals, utilizing genetic engineering and biotechnology processes. Their state-of-the-art cGMP biologics manufacturing facility underscores their commitment to producing innovative human health care products.

Mapi Pharma is a late clinical stage pharmaceutical company focused on developing improved extended-release formulations of existing drugs, which enhances patient compliance and offers potential for extended patent protection. Their pipeline includes products targeting neuropathic pain, epilepsy, schizophrenia, and bipolar disorder, indicating a strong commitment to advancing therapeutic options in these areas.

Bio-Outsourcing specializes in connecting biopharmaceutical and medical device companies with the right preclinical and clinical contract research organizations (CROs), as well as other essential service providers. Their extensive network and efficient approach significantly expedite the development process, enhancing the chances of success for emerging companies in the life sciences sector.

Protalix is a biopharmaceutical company that specializes in developing, producing, and commercializing recombinant therapeutic proteins using its innovative ProCellEx® plant cell-based protein expression system. This platform enables the manufacturing of complex proteins and has the potential for oral delivery of certain therapeutics, positioning Protalix as a pioneer in the biopharmaceutical industry with a commitment to advancing protein-based therapies.

Neopharm Israel is a leading pharmaceutical company dedicated to improving the health and quality of life for patients with serious diseases. Their vision focuses on providing groundbreaking therapies and integrated services, highlighting their commitment to enhance patient well-being and market leadership in the biopharmaceutical sector.

CBI has built a diverse portfolio of biotechnology companies that develop innovative solutions for unmet medical needs. Their collaboration with multinational pharmaceutical companies enhances the potential for groundbreaking biopharmaceutical advancements.

MyBiotics is focused on developing live biotherapeutic products, including probiotics and microbiome treatments, that have clinically proven benefits for human health. Their innovative technologies enhance the delivery and effectiveness of these treatments, positioning them as key players in the biopharmaceutical sector.

The company specializes in innovative technologies and products that enhance diagnostics and treatment in the biopharmaceutical field. Notably, Celsee Diagnostics offers a fully automated system for detecting circulating tumor cells, enabling advanced biomarker analysis at a single-cell level, and Asuragen develops molecular diagnostic products in oncology and genetics.

PharMedica is an innovative developer of polymeric-based delivery platforms that enable controlled and sustained release of drugs, making it highly relevant to the biopharmaceutical field. Their expertise in chemistry and biomedical engineering, along with a focus on medical device development, enhances their capability to support advancements in drug delivery systems.